Trial · NCT06015880
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and tolerability of monsunetuzumab+polatuzumab vedotin+lenalidomide for determination of recommended phase 2 dose | During cycle 1 (cycle=28 days) | Dose limiting toxicity will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
| Secondary | Objective response rate | Up to 2 years | Will be assessed per the Lugano 2014 criteria. |
| Secondary | Complete response rate | Up to 2 years | Will be assessed per the Lugano 2014 criteria. |
| Secondary | Progression free survival | Up to 2 years | Will be assessed per the Lugano 2014 criteria. |
| Secondary | Duration of response | From time of initial response assessment demonstrating at least partial response until disease response assessment that demonstrates progressive disease, assessed up to 2 years | Will be assessed per the Lugano 2014 criteria. |
| Other | CD79b expression levels | At baseline | Will be assessed via ribonucleic acid and immunohistochemistry assessment and correlation with response. |
| Other | Frequency of CD4 T-cells and IFN-gamma+ producing CD4 T-cells | At baseline and up to 2 years | Will be assessed via intracellular flow cytometry. |
| Other | Ultrasensitive determination of cytokine profile | At baseline and up to 2 years | Will be assessed with Luminex assay to identify biomarkers that might predict a response. |
| Other | Efficacy in relapsed/refractory double-expresser lymphoma and double-hit lymphoma | Up to 2 years | |
| Other | Efficacy post chimeric antigen receptor (CAR) T-cell therapy | Up to 2 years | |
| Other | Efficacy post polatuzumab vedotin | Up to 2 years | |
| Other | Percent of patients able to start the triplet therapy | At cycle 2 (cycle=28 days) | |
| Other | Chimeric antigen receptor (CAR) T-cell expansion and persistence | Up to 2 years | |
| Other | CAR T-cell immunophenotypes | Up to 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06015880/registered